A randomized, open-label study assessing the bioequivalence of two formulations of Fingolimod 0.5 mg in healthy subjects

Abstract Fingolimod is an oral agent approved for the treatment of relapsing forms of multiple sclerosis (MS), which has demonstrated efficacy in Phase III trials in patients with relapsing-remitting MS (RRMS). The present study was designed to assess bioequivalence between a fingolimod Test capsule...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Mario Tanguay (Egilea), Thomas Fröhlich (Egilea), Mathieu Drouin (Egilea), Gerald Beuerle (Egilea)
Formatua: Liburua
Argitaratua: SpringerOpen, 2018-03-01T00:00:00Z.
Gaiak:
Sarrera elektronikoa:Connect to this object online.
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Internet

Connect to this object online.

3rd Floor Main Library

Aleari buruzko argibideak 3rd Floor Main Library
Sailkapena: A1234.567
Alea 1 Eskuragarri